A Phase 3 interventional study of Budesonide/Formoterol fumarate dihydrate and Symbicort in Asthma, sponsored by Kindeva Drug Delivery. Completed at 95 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-24.
Sponsored by Kindeva Drug Delivery · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies testing budesonide in Asthma — 6 open to participants now, 6 under way, 3 of them phase 3. Budesonide · Asthma.
Among the 110 studies testing budesonide in Asthma, this one is the 8th largest by enrollment of the 108 interventional ones that give a count, is one of 6 that started in 2016, is one of 51 in phase 3, and was the 90th registered.
4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.
Browse Asthma studies →6 of the 110 studies testing budesonide in Asthma are open now, in 5 countries. Recruiting first, the newest first:
University of Miami · Sites in United States
Ages 18–75
Massachusetts General Hospital · Sites in United States
Ages 18–54
University of KwaZulu · Sites in South Africa
Ages 6–18
Franciscus Gasthuis · Sites in Netherlands
Ages 18+
University of British Columbia · Sites in Canada
Ages 19–49
By country, each count listing its studies:
Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 6 · Phase 3 51 · Phase 4 33
First in 1991; this study’s year is marked. 6 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,762 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 124 across the 108 interventional studies. Of the 94 that completed or were terminated, 35 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
64 of 110 have an industry lead sponsor. The 10 most frequent:
Kindeva Drug Delivery is the lead sponsor of 3 studies on the registry; none are open to participants now.
Kindeva Drug Delivery has 1 study filed under Asthma — fewer than ten, so there is no comparison to draw.
1 of the studies testing budesonide in Asthma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07166939Massachusetts General Hospital45th Multicenter Airway Research Collaboration | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 110 studies testing budesonide in Asthma, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A randomized multiple-dose, placebo-controlled, parallel group design consisting of a 2-week run-in period followed by a 6-week treatment period of the placebo, Test product (Budesonide 80 mcg / Formoterol fumarate dihydrate 4.5 mcg), or Reference product Symbicort® inhalation aerosol.
This is a pivotal trial that will examine therapeutic equivalence of a new generic fixed-dose combination product containing Budesonide 80 mcg / Formoterol fumarate dihydrate 4.5 mcg and reference listed drug (RLD) Symbicort® inhalation aerosol in adult patients with chronic but stable asthma as defined in National Asthma Education and Prevention Program Expert Panel Report 3 (NAEPP 3) guidelines. To ensure adequate study sensitivity the test and reference products should both be statistically superior to placebo (p\<0.05) with regard to the bioequivalent study primary endpoints.
A secondary study objective is the safety and tolerability of the test compound.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Generic Budesonide/Formoterol Fumarate Dihydrate (80mcg/4.5mcg) Inhalation Aerosol, two inhalation twice daily, consisting of a 2-week run-in period followed by a 6-week treatment period
Drug: Budesonide/Formoterol fumarate dihydrate
Symbicort (Budesonide/Formoterol Fumarate Dihydrate) Inhalation Aerosol, two inhalation twice daily, consisting of a 2-week run-in period followed by a 6-week treatment period
Drug: Symbicort
Placebo Inhalation Aerosol, two inhalation twice daily, consisting of a 2-week run-in period followed by a 6-week treatment period
Drug: Placebo
Drug pages: Budesonide · Formoterol
Experimental: Treatment 1
Also known as: Generic Budesonide/Formoterol fumarate dihydrate
Active Comparator: Treatment 2
Also known as: Budesonide/Formoterol fumarate dihydrate
Placebo Comparator: Treatment 3
Area Under the Serial Forced Expiratory Volume in 1 Second (FEV1)
FEV1 Area calculated over 12 hours (measurements at 0, 1, 2, 3, 4, 6, 8, 12 hours post-dose) on Day 1 of treatment. Because this was a primary endpoint, Per Protocol Population used to calculate this endpoint.
Time frame: Day 1
Change From Baseline in FEV1 Measured in the Morning at the End of Treatment Visit
Average predose FEV1 at End of Treatment defined as the average of all predose assessments on Day 42 (+/- 7 days). Baseline was defined as the average of 2 predose FEV1 values obtained on Day 1. The endpoint of baseline-adjusted predose FEV1 at end of treatment was calculated as follows: \[FEV1 at end of treatment\] - \[Baseline FEV1\].
Time frame: Day 1 - Day 49
Number of Participants With Adverse Events
Number of participants reporting at least one adverse event (safety population)
Time frame: 6 Weeks
| Milestone | Treatment 1 | Treatment 2 | Treatment 3 |
|---|---|---|---|
| Started | 613 | 622 | 204 |
| Completed | 598 | 604 | 199 |
| Not completed | 15 | 18 | 5 |
FEV1 Area calculated over 12 hours (measurements at 0, 1, 2, 3, 4, 6, 8, 12 hours post-dose) on Day 1 of treatment. Because this was a primary endpoint, Per Protocol Population used to calculate this endpoint.
| l * hr | Treatment 1 | Treatment 2 | Treatment 3 |
|---|---|---|---|
| Area Under the Serial Forced Expiratory Volume in 1 Second (FEV1) | 4.4453 ± 0.1552 | 4.2790 ± 0.1547 | 1.6876 ± 0.2782 |
Average predose FEV1 at End of Treatment defined as the average of all predose assessments on Day 42 (+/- 7 days). Baseline was defined as the average of 2 predose FEV1 values obtained on Day 1. The endpoint of baseline-adjusted predose FEV1 at end of treatment was calculated as follows: \[FEV1 at end of treatment\] - \[Baseline FEV1\].
| liter | Treatment 1 | Treatment 2 | Treatment 3 |
|---|---|---|---|
| Change From Baseline in FEV1 Measured in the Morning at the End of Treatment Visit | 0.3096 ± 0.0162 | 0.3077 ± 0.0162 | 0.1236 ± 0.0285 |
Number of participants reporting at least one adverse event (safety population)
| Participants | Treatment 1 | Treatment 2 | Treatment 3 |
|---|---|---|---|
| Upper respiratory tract infection | 12 | 15 | 7 |
| Nasopharyngitis | 7 | 11 | 4 |
| Viral upper respiratory tract infection | 6 | 4 | 1 |
| Bronchitis | 3 | 4 | 2 |
| Asthma | 17 | 24 | 39 |
| Cough | 4 | 4 | 3 |
| Headache | 4 | 8 | 2 |
| Chest discomfort | 1 | 0 | 2 |
Collected over Day 1 - Day 70. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment 1 | 0/613 (0%) | 4/613 (0.7%) | 121/613 (19.7%) |
| Treatment 2 | 0/622 (0%) | 3/622 (0.5%) | 138/622 (22.2%) |
| Treatment 3 | 0/204 (0%) | 2/204 (1%) | 71/204 (34.8%) |
| Event | Treatment 1 | Treatment 2 | Treatment 3 |
|---|---|---|---|
| Abdominal painGastrointestinal disorders | 0/613 | 0/622 | 1/204 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/613 | 0/622 | 1/204 |
| cerebrospinal fluid leakageNervous system disorders | 1/613 | 0/622 | 0/204 |
| staphylococcal skin infectionInfections and infestations | 1/613 | 0/622 | 0/204 |
| Alcoholic pancreatitisGastrointestinal disorders | 1/613 | 0/622 | 0/204 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 1/613 | 0/622 | 0/204 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/613 | 1/622 | 0/204 |
| MyositisMusculoskeletal and connective tissue disorders | 0/613 | 1/622 | 0/204 |
| Head injurtInjury, poisoning and procedural complications | 0/613 | 1/622 | 0/204 |
| Event | Treatment 1 | Treatment 2 | Treatment 3 |
|---|---|---|---|
| respiratory, thoracic and mediastinal disordersRespiratory, thoracic and mediastinal disorders | 35/613 | 48/622 | 48/204 |
| asthmaRespiratory, thoracic and mediastinal disorders | 17/613 | 24/622 | 39/204 |
| infections and infestationsInfections and infestations | 54/613 | 58/622 | 20/204 |
| upper respiratory tract infectionInfections and infestations | 12/613 | 15/622 | 7/204 |
| nasopharyngitisInfections and infestations | 7/613 | 11/622 | 4/204 |
| gastrointestinal disordersGastrointestinal disorders | 11/613 | 12/622 | 2/204 |
| injury, poisoning and procedural complicationsInjury, poisoning and procedural complications | 8/613 | 11/622 | 2/204 |
| nervous system disordersNervous system disorders | 9/613 | 10/622 | 2/204 |
| musculoskeletal and connective tissue disordersMusculoskeletal and connective tissue disorders | 8/613 | 10/622 | 2/204 |
| coughRespiratory, thoracic and mediastinal disorders | 4/613 | 4/622 | 3/204 |
Randomized participants who received at least 1 dose of study drug during Treatment Period
| Age, Continuous(years) | Treatment 1 | Treatment 2 | Treatment 3 | Total |
|---|---|---|---|---|
| Mean | 46.3 ± 15.02 | 45.5 ± 14.44 | 45.5 ± 14.78 | 45.8 ± 14.73 |
| Sex: Female, Male(Participants) | Treatment 1 | Treatment 2 | Treatment 3 | Total |
|---|---|---|---|---|
| Female | 375 | 392 | 137 | 904 |
| Male | 238 | 230 | 67 | 535 |
| Ethnicity (NIH/OMB)(Participants) | Treatment 1 | Treatment 2 | Treatment 3 | Total |
|---|---|---|---|---|
| Hispanic or Latino | 153 | 151 | 55 | 359 |
| Not Hispanic or Latino | 460 | 471 | 149 | 1080 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Treatment 1 | Treatment 2 | Treatment 3 | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 0 | 0 | 2 |
| Asian | 5 | 6 | 4 | 15 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 107 | 112 | 43 | 262 |
| White | 490 | 495 | 154 | 1139 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 9 | 9 | 3 | 21 |
| Body Mass Index(kg/m^2) | Treatment 1 | Treatment 2 | Treatment 3 | Total |
|---|---|---|---|---|
| Mean | 30.73 ± 7.667 | 31.27 ± 8.108 | 30.93 ± 7.960 | 30.99 ± 7.900 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2016 to primary completion in Feb 2018, 13 months.
Results were first posted in Aug 2022, 4 years 6 months after primary completion. A results delay was requested in Dec 2018.
Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 13 months is below that.
Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Budesonide · Formoterol
Kindeva Drug Delivery